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Abstract 
Metastasis is a multistage process involving many complex genetic events which 
facilitate the spread and growth of cancer cells at a secondary site. In vivo models of metastasis 
are invaluable to our understanding of the interactions between cancer cells and a variety of cell 
types at the metastatic microenvironment. The objective of this study is to first understand how 
different in vivo models of metastasis can affect the site of secondary growth and second, to 
identify the genetic changes that occur in a single population of cancer cells at various metastatic 
microenvironments.  
For this study, we used a cell line derived from the commonly used and highly metastatic 
MMTV-PymT murine breast cancer model. In order to accurately model metastasis as a multi-
step process we injected the PymT breast cancer cells via five different routes of inoculation. 
Subcutaneous, orthotopic (mammary fat pad), intravascular (tail vein and intracardiac), and 
intratibial injections allow us to assess the metastatic pattern of this cell line along different 
stages in the metastatic cascade. We tracked circulating tumor cells over time using a Xenogen 
In Vivo Imaging System (IVIS) and evaluated metastases based on the site of dissemination, 
morphologic changes, and the genetic profile of the tumor cells at various organ sites (subcutis, 
mammary fat pad, lung, ovary, adrenal gland, and tibia). 
We found that the route of injection did affect the dissemination of PymT tumor cells.  
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 In addition, the MMTV-PymT tumor cells had different morphologic and genetic profiles 
depending on their site of growth (p<0.01). Specifically, E-cadherin, FGFR1, EGF, and MMP9 
expression were greater than 3 fold different in PymT metastases when compared to the cells in 
the mammary gland control. 
We demonstrated that the tumor microenvironment has a site-specific effect on the gene 
expression profile of the PymT cell line. Interestingly, we have also shown that the injection 
route may significantly affect the metastatic potential of tumor cells, and therefore the pathology 
of secondary lesions. This study has significant implications in trying to understand the 
mechanism by which tumor cells disseminate, and also the genetic interactions between tumor 
cells and stroma in various organs of metastasis. 
 
Introduction 
Breast cancer is the second leading cause of cancer related deaths in women, and 
accounts for approximately 40,000 deaths annually (American Cancer Society).  Although 
research has improved the detection and treatment of breast cancer, metastasis still remains the 
most lethal complication of this disease. Metastasis is defined as the process by which cancer 
cells detach from the primary site of origin to disseminate and grow at a distant site. There are 
many complex processes involved in metastasis which hinder our ability to fully understand this 
disease. Cancer cells must acquire the ability to invade through the tissue basement membrane at 
the primary site, intravasate into a blood or lymphatic vessel, survive and extravasate out of the 
vessel, and invade and grow in a foreign tissue microenvironment. There are many molecular 
and biochemical mechanisms which have been discovered to facilitate this multi-stage process, 
although many are still unknown. 
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Animal models are an invaluable tool to the understanding of cancer metastasis (Cardiff 
224-30). These models allow for cells to travel in vivo, to accurately recapitulate the spread of 
disease in humans. In an ideal animal model of breast cancer metastasis, breast cancer initiation 
would occur in the mammary gland, invade out of the primary site and sequentially follow a 
number of stages of progression to seed and grow at a distant site. Unfortunately, this ideal 
model does not exist (Vernon, Bakewell, and Chodosh 199-213). Therefore, it is necessary to use 
injection models which can recapitulate single or multiple stages throughout this process in order 
to study the progression of this disease. Our first objective was to elucidate how different in vivo 
injection models of metastasis can affect the secondary site of growth. Our first hypothesis is that 
the injection route of cancer cells can affect the metastatic potential of the cells to seed in a 
variety of secondary microenvironments. In order to test this hypothesis we have utilized five 
common injection models to study various stages of the multi-stage process of metastasis (Figure 
1.) Mammary fat pad injections or subcutaneous injections allow for the modeling of cells 
leaving the primary site of origin. Alternatively, cardiac or venous injections allow for the 
modeling of cells which have entered the circulation and can then extravasate out of a vessel to 
grow at a secondary site. Finally, injection of cells into the tibia allow for the understanding of 
how breast cancer cells can alter a secondary site of metastasis, with bone being the most 
common site of breast cancer metastasis. 
In addition to determining where breast cancer cells metastasize, our second objective is 
to study the morphologic and genetic changes that can occur in cancer cells when they reach 
various tissue microenvironments. Our second hypothesis is that breast cancer cells will undergo 
different morphologic and genetic changes depending on the site of dissemination, which may 
allow them to survive and grow at that site. This is the first study to evaluate a commonly used 
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breast cancer cell line using various routes of injection in order to understand both the pattern of 
metastasis, as well as the genetic and morphologic changes that occur in that cell line in various 
microenvironments. Implications from this study can further our understanding of both the 
molecular mechanisms related to metastasis, as well as the genetic interactions between breast 
cancer cells and stroma in various metastatic microenvironments. 
 
Materials and Methods 
Highly aggressive Mouse Mammary Tumor virus- Polyoma Middle T antigen (MMTV-
PymT) cells were selected for this study in order to reliably and reproducibly model metastasis 
(Borowsky et al. 47-59). Advantages of this model include the rapid formation of metastasis to 
the lung in virtually 100%  of transgenic animals within 20 weeks of age (Borowsky et al. 47-
59); as well as an accurate model of multi-stage progression similar to human disease (Qiu et al. 
5973-81). Additionally, the isolation of these cells from a primary mouse breast tumor allows for 
injection into strain matched, immunocompetent animals to allow for the involvement of the 
immune system in metastasis (Lin et al. 2113-26).  
MMTV-PymT cells were cultured using standard laboratory protocols for aseptic cell 
culture. In order to monitor metastasis in vivo cells were transfected with a firefly luciferase gene 
construct (YFP-luciferase-pcDNA3.1). Cells were characterized post-transfection and 
determined to maintain proliferation and tumorigenic properties identical to the parental line 
(data not shown). Cells were harvested at approximately 70% confluence, 95-100% viability, and 
verified mycoplasma infection free before injection. For all injections, cells were resuspended in 
sterile DPBS and kept on ice until inoculation. FVB/N mice (Jackson Laboratories) were injected 
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at 6-8 weeks of age and housed in accordance with the approved guidelines set forth by The 
Ohio State University Institution for Animal Care and Usage Committee (IACUC). 
Number of cells and technique for injection at each site were determined based on both 
previous literature and original design as approved by The Ohio State University IACUC. For all 
injections, animals were anesthetized using 3% isoflurane gas and maintained at 2% isoflurane 
on a rodent heating pad. The injection site was sterilized using 70% ethyl alcohol. For both 
orthotopic (mammary fat pad) and heterotopic (subcutaneous) injections, 5 million MMTV-
PymT cells were injected in 50ul of PBS at either site respectively using a 25G needle (N=10 
animals each) (Borowsky et al. 47-59). In order to directly inject cells into the circulatory system 
cells were injected into either the left cardiac ventricle (N=20) or the lateral tail vein (N=11). For 
intracardiac injections, mice were placed in a position of dorsal recumbency under anesthesia. A 
Vevo 660 small animal ultrasound (VisualSonics) was used to visualize the left cardiac ventricle 
while 100,000 MMTV-PymT cells were simultaneously injected in 100µl into the heart using a 
27G needle (Phadke et al. 809-17). Injection of cells into the arterial circulation was confirmed 
through ultrasound visualization of the cells in the left ventricular chamber of the heart, as well 
as a pulsing of blood in the needle upon injection. Alternatively, venous inoculation was 
performed by injecting 2 million MMTV-PymT cells in 200µl of PBS into the dilated lateral tail 
vein using a 27G needle (Jessen et al. R157-R169). Finally, intratibial injections (N=10) were 
performed using a 26G needle by drilling through the patellar ligament and the tibial crest and 
injecting 100,000 MMTV-PymT cells in 20µl volume into the medullary canal (Tannehill-Gregg 
et al. 19-31).  
Metastasis was tracked using bioluminescent imaging (IVIS, Xenogen) and mice were 
euthanized using 100% CO2 at the first clinical sign of disease as approved by The Ohio State 
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University IACUC. Final metastatic lesions were confirmed using gross evaluation at necropsy, 
radiography, and histopathology. Immunohistochemistry for Ki67 was performed on formalin 
fixed tumors from each site (N=3) to evaluate differences in proliferation rate of MMTV-PymT 
cells at each anatomical location. 
For genetic evaluation of MMTV-PymT cells, RNA was isolated from representative 
metastases (N=3) and reverse transcribed into cDNA. RT2 Profiler PCR Arrays were then used to 
evaluate a set of 88 pathway-focused genes related to cancer pathogenesis. Arrays were 
performed according to the manufacturer’s protocol (SA Biosciences, Frederick, MD). The 
resulting values were analyzed for pathway-focused clustering of genes with a statistically 
significant up or down regulation. Additionally, only genes showing a 4 fold or greater change or 
were considered for final analysis. 
Numerical data are expressed as means ± S.D. Statistical differences were performed 
using a students T-test with a level of significance at p<0.05 unless stated as otherwise. 
 
Results 
MMTV-PymT metastasis is injection site dependent. Overall, the route of injection did affect the 
metastatic potential of MMTV-PymT cells (figure 2). We did not observe metastases following 
orthotopic or heterotopic, or intratibial injections. However, both intravascular routes of injection 
resulted in metastases with different organs of colonization. Tail vein injection of MMTV-PymT 
cells resulted in 9/11 mice with lung metastases and two of these mice also had accompanying 
ovarian metastases. Following intracardiac injections 7 mice had no metastases, 13 had ovarian 
metastases, 6 had adrenal gland metastases, and 3 had bone metastases to the skull or humerus, 
with some mice resulting in multiple metastases. 
6 
MMTV-PymT tumors exhibit multiple phenotypic differences depending on the site of metastasis. 
To assess the pathologic significance of the MMTV-PymT lesions, the tumors were examined 
for histologic evidence of poor prognosis. Morphologic changes in mitotic index, nuclear 
morphology, and percent of necrosis were all evaluated at the six sites of growth (breast, lung, 
ovary, tibia, adrenal gland, and subcutis). Overall, MMTV-PymT lesions were poorly 
differentiated with a high level of anaplastic and multi-nucleated cells. These characteristics 
were seen to a higher degree in the ovary and subcutis when compared to other sites. We also 
evaluated the degree of proliferation of MMTV-PymT cells at each site through 
immunohistochemical staining for Ki67. Overall, we found that MMTV-PymT cells growing in 
the subcutis had the highest percentage of cells dividing (46%) followed by ovary (41%), breast 
(38%), adrenal (31%), lung (29%), and bone (16%). This therefore suggests that the tumor 
microenvironment may affect the rate of proliferation or growth of MMTV-PymT cells, with the 
subcutis giving the greatest growth advantage to MMTV-PymT cells (Figure 4.) 
 
MMTV-PymT cells undergo differential gene expression depending on the site of growth (N=3).  
Based on a set of 88 pathway focused genes related to cancer progression we found 36 genes that 
were statistically up or down regulated in MMTV-PymT cells in various tissue 
microenvironments (p < 0.05). These changes were then clustered into pathways of importance 
such as adhesion and metastasis, cell cycle and apoptosis, or angiogenesis (Figure 5.) 
Hierarchical clustering suggested that the genetic profile of MMTV-PymT cells in the bone 
microenvironment was most distinct from the other organ sites. Furthermore, angiogenesis and 
metastasis genes were greater up regulated in the MMTV-PymT cells in bone verses a significant 
down regulation at the other sites. 
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 Additionally, there were five genes that had a greater than four-fold difference in gene 
expression when compared to the cells in the mammary gland control: E-cadherin, epidermal 
growth factor receptor (EGFR), fibroblast growth factor receptor-2 (FGFR2), matrix 
metalloproteinase 9 (MMP9) and endothelial-specific receptor tyrosine kinase (Tek). 
Interestingly, these differences in gene expression were dependent on the site of MMTV-PymT 
growth. MMTV-PymT cells in the bone had the greatest fold change in gene expression with a 4-
fold significant up regulation of EGFR, 27-fold up regulation of fibroblast FGFR2, 44-fold up 
regulation of MMP9 and 4-fold up regulation of Tek. FGFR2 expression in MMTV-PymT cells 
was also significantly up regulated in the lung metastases (9-fold), ovary metastases (4-fold), and 
adrenal gland metastases (14-fold). Interestingly, the expression of E-cadherin in the ovary 
metastases were down regulated 6-fold in the ovary when compared to other sites, and this result 
was confirmed by immunohistochemistry (data not shown). Taken together, these data suggest 
that the expression of specific genes can be altered in MMTV-PymT cells depending on the site 
of growth. 
 
Discussion 
 In vivo models are critical for the elicitation of molecular mechanisms involved in breast 
cancer pathogenesis. In particular, the MMTV-PymT model has been key to the identification of 
important cancer-related molecules such as tyrosine kinases, and the phosphorylation of 
phosphatidylinositol 3-kinases (Dilworth 951-56). However, few studies have looked at the 
relevance of the injection site in progression or metastasis of breast cancer cells. This is the first 
study to characterize the metastatic, morphologic, and genetic changes in MMTV-PymT cells 
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following multiple injection models of metastasis. Furthermore, this study also supports the role 
of the tumor microenvironment as a critical factor in the pathogenesis of metastatic disease. 
 The tumor microenvironment is now recognized as an important and prominent factor in 
tumor progression. Multiple studies have defined the role of different compartments in the 
microenvironment which facilitate various stages of progression such as proliferation (Yashiro et 
al. 307-13), growth (Schor 223-48), angiogenesis (Fainaru et al. 522-29) and survival of cancer 
cells (Khan et al.). Loss of heterozygosity (LOH) studies have also revealed that multiple stromal 
targets undergo genetic changes to support the growth of breast cancer cells (Fukino et al. 7231-
36). Aside from growth at the primary site, the microenvironment is also known to play a role in 
the regulation of metastasis by immune cell recruitment, cytokine secretion, structural support, 
among other actions (Joyce and Pollard 239-52). Interestingly, many studies also suggested that 
there is tissue-specific tropism for breast cancer cells to metastasize to certain organs (Kang 129-
38) based on the pattern of dissemination in vivo. However, this study is the first to show that all 
these factors may be related to not only the metastatic microenvironment, but also the route of 
inoculation. Specifically, this study suggests that changes in cell morphology and gene 
expression in the MMTV-PymT cells may depend on the route of dissemination, as well as 
molecular cues from the microenvironment which provide a tissue specific growth advantage. 
 There are many morphologic characteristics that are associated with aggressive tumors 
and therefore poor prognosis (Cardiff 224-30). These data suggest that MMTV-PymT cells not 
only exhibit these negative morphologic characteristics, but also that the degree of morphologic 
variation in these tumors depend on the site of growth or metastasis. Measurements of mitotic 
index and percent necrosis suggest that MMTV-PymT cells in the subcutis have a more 
aggressive phenotype verses other sites of growth. Additionally, proliferation rates of MMTV-
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PymT cells change depending on the site of growth as evidenced through a greater percentage of 
Ki67 positive MMTV-PymT cells in the subcutis verses other sites. Taken together, these data 
suggest that the morphology and proliferation of breast cancer cells can change depending on the 
site of growth. This finding may therefore help in defining the role of morphologic changes in 
determining the patient prognosis as well as strategies for treatment. 
 In addition to phenotypic changes, we have identified 5 genes (E-cadherin, EGFR, 
FGFR2, MMP9 and Tek) which are significantly up or down regulated in MMTV-PymT cells 
depending on the route of injection and site of metastasis. Furthermore, these genes have all been 
previously documented to be important in the adhesion, progression and metastasis of breast 
cancer cells in numerous studies. These data demonstrate that while genes such as FGFR2 may 
be significantly up regulated at multiple sites of metastasis (ovary, adrenal, bone, lung), other 
genes such as E-cadherin are significantly regulated at only one site (ovary). This therefore 
suggests that specific genes may play a critical role in giving a specific survival or growth 
advantage to MMTV-PymT cells in a site-specific manner.  
 In conclusion, this study is the first to evaluate the phenotypic and genetic changes in 
MMTV-PymT cells following multiple routes of inoculation. We do not currently know if the 
circulation patterns and dissemination of cancer cells throughout the body may have an impact 
on the pathogenesis or genetic expression of tumor cells at the final site of colonization. 
However, these results suggest that morphologic and genetic changes do occur in cancer cells 
depending on the site of growth and the mode of injection. Therefore, breast cancer progression 
and metastasis is affected by not only the tumor microenvironment, but also the route of 
metastasis to that microenvironment. 
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Figure 1. Injection of MMTV-PymT cells via different anatomical routes accurately 
recapitulate the multistage process of metastasis. 
 
 
 
Metastasis is a multistage process involving invasion of cells out of the primary site, 
intravasation into a blood or lymph vessel, extravasation out of circulation, and survival and 
growth at a secondary site. Currently, there are no models which accurately model this process 
from initiation to metastasis. Therefore, injection models are invaluable to understanding this 
complex process. The goal of this study is to model metastasis using all the available models of 
metastasis in order to accurately recapitulate and study this process in multiple stages.  
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Figure 2. MMTV-PymT metastasis is injection site dependent. 
 
 
 
 
 
We found that the route of injection did affect the dissemination of MMTV-PymT tumor cells. 
We found no metastasis after mammary fat pad injection (N= 0/10), or subcutaneous injection 
(N= 0/10). Lung metastases were commonly detected after tail vein injection (N= 9/11), along 
with ovary metastases in a smaller percentage of mice (N= 2/11). Interestingly, alternative 
intravascular routes of injection (intracardiac) resulted in a different pattern of dissemination: 
ovary (N= 13/20), adrenal gland (N= 6/20), and bone (N= 3/20). Finally, no metastases were 
observed following intratibial injections although mild osteolysis was visible via radiographic 
and histologic evaluation. 
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Figure 3. MMTV-PymT cells undergo phenotypic differences at various sites of metastasis. 
 
 
 
Metastases were detected through gross examination, bioluminescent imaging, and 
histopathology. Morphologic changes were seen in MMTV-PymT cells depending on the site of 
growth. Specifically, cells exhibited differences in cell morphology, mitotic index, and percent of 
necrosis. These findings are significant in determining the aggressiveness of the cells at various 
sites, and therefore the prognosis for the patient. 
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Figure 4. The rate of proliferation of MMTV-PymT cells changes depending on the site of 
metastasis. 
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(A.) Proliferation was measured through immunohistochemistry for Ki67 positive cells. The 
number of Ki67 positive cells per 100 cells was measured in 3 fields of view, on three mice per 
group (N=9 measurements per site). (B.) Overall, MMTV-PymT cells growing in the subcutis 
(46%) had the highest percentage of cells dividing followed by ovary (41%), breast (38%), 
adrenal (31%), lung (29%), and bone (16%). This therefore suggests that the tumor 
microenvironment may affect the rate of proliferation or growth of MMTV-PymT cells. 
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Figure 5. MMTV-PymT cells undergo differential expression of 36 pathway-focused genes 
depending on the site of growth.  
 
 
 
 
RNA was isolated from MMTV-PymT tumors at six different sites of growth (N=3). Next, Q-
RT-PCR was used to examine a set of 88 pathway focused genes related to cancer progression 
(RT2 Profiler, SA Biosciences). Overall, 36 genes were significantly up or down-regulated when 
compared to the MMTV-PymT cells in the mammary gland control (p<0.05). Furthermore, 
hierarchical clustering of these genes reveals pathways of importance such as adhesion, cell 
cycle and apoptosis, angiogenesis, and metastasis.  
Therefore, this suggests that differences in growth and metastasis of MMTV-PymT cells may be 
related to certain pathways that play a role in the tumor microenvironment.
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Figure 6.  Fold differences in MMTV-PymT gene expression change depending on the site 
of growth or metastasis. 
 
 
 
Five genes had a greater than four fold difference in gene expression when compared to the 
MMTV-PymT cells in the mammary gland control: E-cadherin, epidermal growth factor receptor 
(EGFR), fibroblast growth factor receptor-2 (FGFR2), matrix metalloproteinase 9 (MMP9) and 
endothelial-specific receptor tyrosine kinase (Tek). These fold changes in gene expression were 
dependent on the site of growth or metastasis (p<0.05). MMTV-PymT cells in the bone had the 
greatest fold change in gene expression with significant up regulation of EGFR (4-fold), FGFR2 
(27-fold), MMP9 (44-fold) and Tek (4-fold). Up regulation of FGFR2 was also seen in lung 
metastases (9-fold), ovary metastases (4-fold) and adrenal metastases (14-fold). Interestingly, E-
cadherin was significantly down regulated MMTV-PymT ovary metastases (6-fold). 
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